Walden Biosciences

Executive Summary

Walden Biosciences is a private biotechnology company headquartered in Cambridge, Massachusetts, founded in 2019. The company is dedicated to developing novel, disease-modifying therapies for kidney disease, an area with significant unmet medical need. Walden's pipeline spans biologics, antibodies, and small molecules, all designed to directly target the kidney and transform treatment paradigms. Currently in Phase 2 clinical development, Walden is progressing its lead candidates through the clinic. The company's approach focuses on addressing the root causes of kidney dysfunction, potentially offering advantages over current symptomatic treatments. With a strong scientific foundation and a clear focus on renal disease, Walden is positioned to become a key player in nephrology. Its early-stage pipeline and private status suggest that upcoming clinical data and potential partnerships will be critical to its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout for lead candidate60% success
• Q4 2026Announcement of partnership or licensing deal50% success
• Q1 2027Series B or later-stage financing round75% success